ValuEngine lowered shares of BioScrip, Inc. (NASDAQ:BIOS) from a hold rating to a sell rating in a research note released on Tuesday morning.
Other equities research analysts also recently issued research reports about the stock. Barrington Research lifted their price target on shares of BioScrip to $3.50 and gave the stock an outperform rating in a research note on Monday, June 26th. Zacks Investment Research upgraded shares of BioScrip from a hold rating to a buy rating and set a $3.00 price target on the stock in a research note on Wednesday, July 5th. Finally, BidaskClub downgraded shares of BioScrip from a strong-buy rating to a buy rating in a research note on Tuesday. One equities research analyst has rated the stock with a sell rating and five have assigned a buy rating to the stock. BioScrip has an average rating of Buy and an average target price of $3.50.
BioScrip (BIOS) opened at 2.66 on Tuesday. BioScrip has a 52-week low of $0.98 and a 52-week high of $3.43. The company’s market capitalization is $321.81 million. The stock has a 50 day moving average of $2.77 and a 200-day moving average of $1.96.
BioScrip (NASDAQ:BIOS) last posted its quarterly earnings results on Thursday, May 4th. The company reported ($0.16) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.12) by $0.04. The business had revenue of $217.80 million for the quarter, compared to analysts’ expectations of $230.23 million. During the same quarter in the prior year, the company earned ($0.17) EPS. BioScrip’s quarterly revenue was down 8.7% on a year-over-year basis. On average, equities analysts forecast that BioScrip will post ($0.38) earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: This story was originally posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this story on another domain, it was illegally copied and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be read at https://stocknewstimes.com/2017/08/05/valuengine-downgrades-bioscrip-inc-bios-to-sell.html.
Large investors have recently modified their holdings of the stock. Sheets Smith Wealth Management increased its stake in shares of BioScrip by 33.9% in the first quarter. Sheets Smith Wealth Management now owns 110,508 shares of the company’s stock valued at $188,000 after buying an additional 27,998 shares in the last quarter. Gilder Gagnon Howe & Co. LLC purchased a new stake in shares of BioScrip during the first quarter valued at approximately $7,422,000. FMR LLC increased its stake in shares of BioScrip by 3,489.1% in the fourth quarter. FMR LLC now owns 3,529,795 shares of the company’s stock valued at $3,671,000 after buying an additional 3,431,447 shares in the last quarter. Teachers Advisors LLC increased its stake in shares of BioScrip by 14.0% in the fourth quarter. Teachers Advisors LLC now owns 162,778 shares of the company’s stock valued at $169,000 after buying an additional 20,000 shares in the last quarter. Finally, Perkins Capital Management Inc. increased its stake in shares of BioScrip by 4.2% in the first quarter. Perkins Capital Management Inc. now owns 310,500 shares of the company’s stock valued at $528,000 after buying an additional 12,500 shares in the last quarter. Institutional investors own 83.22% of the company’s stock.
About BioScrip
BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for BioScrip Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
